These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

141 related articles for article (PubMed ID: 1934454)

  • 41. ["Eosinophilia-myalgia" syndrome due to L-tryptophan containing products. Cooperative evaluation of French Regional Centers of Pharmacovigilance. Analysis of 24 cases].
    Castot A; Bidault I; Bournerias I; Carlier P; Efthymiou ML
    Therapie; 1991; 46(5):355-65. PubMed ID: 1754978
    [TBL] [Abstract][Full Text] [Related]  

  • 42. AHR activation by tryptophan--pathogenic hallmark of Th17-mediated inflammation in eosinophilic fasciitis, eosinophilia-myalgia-syndrome and toxic oil syndrome?
    Rieber N; Belohradsky BH
    Immunol Lett; 2010 Feb; 128(2):154-5. PubMed ID: 19941898
    [TBL] [Abstract][Full Text] [Related]  

  • 43. [Polyneuropathy and fasciitis in eosinophilia-myalgia syndrome].
    Hetzel W; Dangel P; Molitor H
    Fortschr Neurol Psychiatr; 1991 Oct; 59(10):425-31. PubMed ID: 1662183
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Chronic fatigue: a peculiar evolution of eosinophilia myalgia syndrome following treatment with L-tryptophan in four Italian adolescents.
    Priori R; Conti F; Luan FL; Arpino C; Valesini G
    Eur J Pediatr; 1994 May; 153(5):344-6. PubMed ID: 8033924
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Eosinophilic cholecystitis as a possible late manifestation of the eosinophilia-myalgia syndrome.
    Hepburn A; Coady A; Livingstone J; Pandit N
    Clin Rheumatol; 2000; 19(6):470-2. PubMed ID: 11147758
    [TBL] [Abstract][Full Text] [Related]  

  • 46. L-tryptophan-induced eosinophilia-myalgia syndrome. I. Report of two cases with pseudoxanthoma-elasticum-like skin changes.
    Mainetti C; Schmied E; Masouyé I; Chavaz P; Saurat JH
    Dermatologica; 1991; 183(1):57-61. PubMed ID: 1769422
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Eosinophilia-myalgia syndrome: coming to grips with a new illness.
    Kilbourne EM
    Epidemiol Rev; 1992; 14():16-36. PubMed ID: 1289111
    [TBL] [Abstract][Full Text] [Related]  

  • 48. [Eosinophilia-myalgia syndrome].
    Kotake S; Kashiwazaki S
    Nihon Rinsho; 1992 Jul; 50(7):1650-5. PubMed ID: 1404896
    [TBL] [Abstract][Full Text] [Related]  

  • 49. The eosinophilia-myalgia syndrome and tryptophan.
    Belongia EA; Mayeno AN; Osterholm MT
    Annu Rev Nutr; 1992; 12():235-56. PubMed ID: 1503805
    [No Abstract]   [Full Text] [Related]  

  • 50. The eosinophilia-myalgia syndrome--guidelines for patient care.
    Hertzman PA; Kaufman LD; Love LA; Mease PJ; Philen RM; Pincus T; Rosenberg NL; Silver R; Varga J; Clauw DJ
    J Rheumatol; 1995 Jan; 22(1):161-3. PubMed ID: 7699664
    [No Abstract]   [Full Text] [Related]  

  • 51. Gastrointestinal involvement in L-tryptophan (L-Trp) associated eosinophilia-myalgia syndrome (EMS).
    De Schryver-Kecskemeti K; Bennert KW; Cooper GS; Yang P
    Dig Dis Sci; 1992 May; 37(5):697-701. PubMed ID: 1563309
    [TBL] [Abstract][Full Text] [Related]  

  • 52. [Eosinophilia-myalgia syndrome. The clinical spectrum expands].
    Schnabel A; Gross WL
    Z Rheumatol; 1992; 51(1):1-2. PubMed ID: 1574930
    [No Abstract]   [Full Text] [Related]  

  • 53. Eosinophilia-myalgia syndrome among the non-L-tryptophan users and pre-epidemic cases.
    Sullivan EA; Staehling N; Philen RM
    J Rheumatol; 1996 Oct; 23(10):1784-7. PubMed ID: 8895159
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Pathogenesis of L-tryptophan eosinophilia myalgia syndrome.
    Sternberg EM
    Adv Exp Med Biol; 1996; 398():325-30. PubMed ID: 8906284
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Cutaneous manifestations of the L-tryptophan-associated eosinophilia-myalgia syndrome: a spectrum of sclerodermatous skin disease.
    Kaufman LD; Seidman RJ; Phillips ME; Gruber BL
    J Am Acad Dermatol; 1990 Dec; 23(6 Pt 1):1063-9. PubMed ID: 2273104
    [TBL] [Abstract][Full Text] [Related]  

  • 56. [Eosinophilia-myalgia syndrome with fasciitis and interstitial myositis after L-tryptophan administration].
    Bartz-Bazzanella P; Genth E; Pollmann HJ; Schröder JM; Völker A
    Z Rheumatol; 1992; 51(1):3-13. PubMed ID: 1574934
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Rapid HPLC screening method for contaminants found in implicated L-tryptophan associated with eosinophilia myalgia syndrome and adulterated rapeseed oil associated with toxic oil syndrome.
    Williamson BL; Tomlinson AJ; Hurth KM; Posada de la Paz M; Gleich GJ; Naylor S
    Biomed Chromatogr; 1998; 12(5):255-61. PubMed ID: 9787895
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Central and peripheral nervous system involvement in the L-tryptophan associated eosinophilia myalgia syndrome.
    Tolander LM; Bamford CR
    Int J Neurosci; 1991 Nov; 61(1-2):69-75. PubMed ID: 1809736
    [TBL] [Abstract][Full Text] [Related]  

  • 59. The lessons of eosinophilia-myalgia syndrome.
    Duffy J
    Hosp Pract (Off Ed); 1992 Apr; 27(4A):65-9, 73-80, 83-90. PubMed ID: 1560091
    [No Abstract]   [Full Text] [Related]  

  • 60. The eosinophilia-myalgia syndrome and related disorders.
    Kaufman LD
    Recenti Prog Med; 1991 May; 82(5):286-90. PubMed ID: 1887155
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.